The content is available as a PDF (113.2 KB).
. 2021 May 28;156:S18. doi: 10.1016/S0169-5002(21)00241-5
Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital
Rebecca Sen
, Rafiqul Islam Islam
, Harriet Baker
, Samuel Kim
Rebecca Sen
Find articles by Rebecca Sen
Rafiqul Islam Islam
Find articles by Rafiqul Islam Islam
Harriet Baker
Find articles by Harriet Baker
Samuel Kim
Find articles by Samuel Kim
Issue date 2021 Jun.
Copyright © 2021 Elsevier B.V. Published by Elsevier B.V. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC8159539